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Abstract   
 
Background:  The occurrence of skeletal related events (SREs) in patients with solid 
tumors and multiple myeloma is a concern for both patient and provider due to the 
subsequent morbidity and risk for further complications. SREs have been defined by 
researchers as pathological fracture, radiation or surgery to bone, or spinal cord 
compression.  Therapies that prevent SREs are an important supportive measure in the 
management of cancer patients. 
Method:  An exhaustive search of available medical literature was performed using the 
following databases: Medline, CINAHL, and Web of Science. A cited reference search 
was performed using Web of Science. The keywords used were denosumab, RANK 
ligand, bisphosphonates, solid tumors, and multiple myeloma. 
Results:  Three RCTs that met inclusion criteria were analyzed and were relevant for the 
purposes of this systematic review. Results are as follows: Median time, in months, to 
first on-study SRE in Fizazi et al, (denosumab: 20.7, zoledronic acid: 17.1; HR, 0.82), 
Stopeck et al (denosumab: not reached, zoledronic acid: 26.4; HR, 0.82), Henry et al 
(denosumab: 20.6, zoledronic acid: 16.3; HR, 0.84). 
Conclusion:  Denosumab has proven to be better than bisphosphonates (particularly 
zoledronic acid) for the prevention of skeletal related events in patients with solid tumor 
malignancy or multiple myeloma. Denosumab is easier to administer, can be used 
without dose adjustment for renal impairment or renal monitoring, and has lower 
incidence of renal failure and acute phase reactions. Monitoring for hypocalcemia is 
important, and a supplement should be given as indicated. There is not a significant 
difference between incidence of osteonecrosis of the jaw (ONJ), or overall survival and 
disease progression with either denosumab or bisphosphonates. 
Keywords: Denosumab, RANK ligand, Bisphosphonates, solid tumors, multiple 
myeloma 
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Denosumab Versus Bisphosphonates in the Prevention of Skeletal Related Events in 
Patients With Solid Tumors or Multiple Myeloma 
BACKGROUND 
Overview of Problem 
 Skeletal related events (SREs) have been defined by researchers as pathological 
fracture, radiation or surgery to the bone, or spinal cord compression.1-3 The frequency of 
SREs in women with breast cancer, as an example, was reported in a study published in 
1998 as follows: hypercalcemia of malignancy 19%, pathological fracture of a long bone 
19%, spinal cord compression 10%.4 The occurrence of SREs is patients with solid 
tumors and multiple myeloma is a concern for both patient and provider due to the 
subsequent morbidity and risk for further complications. Coleman5 sets forth the 
following list, which describes possible outcomes of skeletal complications: pain, 
impaired mobility, hypercalcemia, pathological fracture, spinal cord compression or 
nerve root compression, and bone marrow infiltration. These problems present their own 
risks and have potential to lead to additional sequelae, including known adverse effects of 
opioid use for pain management, risks of surgical management or radiation therapy, end-
organ damage or mortality from hypercalcemia, paralysis secondary to untreated spinal 
cord compression, 5 and others that will not be addressed here.  
 Hypercalcemia- One source 6 states, “Hypercalcemia is the most common 
paraneoplastic endocrine syndrome, occurring in 25% of malignancies. In the great 
majority of patients (98%), the identity of the tumor is apparent at the time of 
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presentation, and the prognosis is poor, as most patients with hypercalcemia of 
malignancy do not survive beyond 6 months.” Hypercalcemia of malignancy occurs most 
commonly as a result of parathyroid hormone related protein (PTHrP), in addition to 
other endocrine pathways of bone resorption.6 In multiple myeloma, “Hypercalcemia and 
lytic bone lesions are among the diagnostic criteria…” 6 Hypercalcemia can lead to 
problems for the patient, among the more severe of which are renal failure and cardiac 
arrhythmia potentially leading to death. 5 Because bone resorption is a significant cause 
of hypercalcemia of malignancy,6 this condition must be treated with the most aggressive 
(and least toxic) therapy available. 
Pathophysiology of events associated with bone metastasis- In the text 
Greenspan’s Basic & Clinical Endocrinology 6 (chapter 21 titled Humoral Manifestations 
of Malignancy), the author gives the following explanation of the humoral mediators 
associated with bone resorption in malignancy.   
When tumor expression of PTHrP results in inappropriately high levels of PTHrP 
that reaches bone cells through the circulation or following synthesis in the bone 
microenvironment, a vicious cycle can ensue. PTHrP stimulates the expression of 
RANKL (receptor activator of NF-κB ligand) by osteoblasts. RANKL, the 
primary gatekeeper modulating bone resorption in health and disease, stimulates 
osteoclast differentiation and function via binding to its receptor, RANK, on 
osteoclasts and their precursors. Increased numbers of activated osteoclasts are 
generated both by the local release of PTHrP, in the case of bone metastases, or 
by high levels of the hormone [calcitonin] produced by tumor cells in 
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extraskeletal sites. Both mechanisms cause enhanced bone resorption. In the case 
of bone metastases, sequestered growth factors, such as transforming growth 
factor (TGF)-beta, released locally from the bone matrix during resorption, further 
enhance tumor cell secretion of PTHrP. 
This process illustrates one mechanism for the development of SREs in cancer patients. 
Therapeutic agents that act to inhibit the pathological process in bone, thereby decreasing 
the rate of SREs, are beneficial and essential to the overall management of the patient.7  
Purpose of Study 
 It is well known in oncology that bisphosphonates (a class of drugs, one of which 
is zoledronic acid) are effective in the prevention of SREs, the treatment of bone pain 
associated with malignancy, as well as hypercalcemia of malignancy.7-10 However, like 
most prescribed therapeutic agents, bisphosphonates are not 100 percent effective and are 
known to be associated with severe adverse events. These include renal toxicity, 
potentially leading to renal failure, particularly in patients with known renal impairment 
or risk factors for such.9 Because of this, dose adjustments for renal impairment and 
continued renal monitoring during therapy are required.9 Another rare, but serious 
adverse event is osteonecrosis of the jaw (ONJ), which has been shown to occur more 
often in patients with recent history of dental extraction.9,11 Other adverse effects include 
acute-phase reactions, particularly a flu-like syndrome, bone, joint or muscular pain, and 
many others.1-3, 9   
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 The purpose of this review is to compare the effectiveness of bisphosphonates and 
the novel therapeutic agent, denosumab, a human monoclonal antibody against RANKL. 
Research 1-3 shows denosumab is effective in reducing SREs without the need for dose 
adjustments for renal impairment. If denosumab proves to be more effective and has less 
negative side effects, it could prove to be a better option. 
METHODS 
 Search strategy: 
 An exhaustive search of medical literature was performed using the following 
databases: Medline, CINAHL, and Web of Science. The following keyterms were used: 
denosumab, RANK ligand, bisphosphonates, solid tumors, and multiple myeloma. 
 Eligibility criteria:  
 Studies chosen for review include double blind, randomized, placebo controlled 
trials involving patients with either solid tumor or multiple myeloma who have been 
assigned to receive either denosumab or a bisphosphonate for the prevention of SREs 
associated with bone metastasis.  
 Validity assessment: 
 Validity and risk of bias of chosen studies was assessed via standard JAMA 
critical appraisal format, as well as GRADE criteria. 
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RESULTS 
 Comprehensive search of previously mentioned databases initially yielded 369 
results. The titles and abstracts of each of these were screened and 366 were excluded 
because they did not meet the inclusion criteria. The full text of 3 studies whose abstracts 
met inclusion criteria were assessed and included in this systematic review.  See Table II, 
Summary of Findings. 
  In 2011 Fizazi et al1 conducted a double blind, randomized controlled trial of 
1901 men across 342 centers in 39 countries. Participants were age ≥18 years with 
castration resistant prostate cancer, a solid tumor. Study participants were randomized 
(via computer generation by an individual outside the study) into two groups to receive 
either 120 mg SQ denosumab plus IV placebo every 4 weeks or 4mg IV infusion of 
zoledronic acid plus SQ placebo every 4 weeks (or equivalent creatinine clearance 
adjusted dose in patients with baseline creatinine ≤1mL/s). There were 950 participants in 
the denosumab group and 951 in the zoledronic acid group.  Participants in each group 
had similar baseline characteristics, including age, race, prior occurrence of SRE, ECOG 
performance status, creatinine clearance, bone turnover markers, time from diagnosis of 
prostate cancer to randomization (months), time from diagnosis of bone metastasis to 
randomization (months), presence of visceral metastasis, hemoglobin concentration, PSA 
at randomization and Gleason score at diagnosis. 1 
The primary endpoint was time to first on-study skeletal related event, assessed 
for noninferiority. The secondary endpoint, which was assessed if noninferiority was 
found, was time to first on-study SRE for superiority as well as time to first and 
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subsequent SREs. The study addressed potential exploratory endpoints: overall survival, 
investigator-assessed overall disease progression (visceral distant metastatic disease, 
locoregional progression, and biochemical progression and excluding SREs), PSA 
concentration during the study and change in bone turnover markers from baseline. 
Additionally, the following safety endpoints (measured at baseline and every 4 weeks) 
were measured: frequency of treatment-emergent adverse events, changes in routine 
chemistry and hematology lab values, and presence of neutralizing anti-denosumab 
antibodies.1 
 Participants included in the study had histologically confirmed prostate cancer, 
current or prior radiographic evidence of at least one bone metastasis, documented failure 
of at least one hormonal therapy (using PSA level), adequate organ function, an albumin-
adjusted serum calcium concentration of 2-2.9 mmol/L, and Eastern Cooperative 
Oncology Group (ECOG) performance status of 0, 1, or 2.  Participants were excluded if 
they had current or prior bisphosphonate use (IV or PO) for bone metastasis (this was 
permitted if it was used for treatment of osteoporosis only), planned radiation or surgery 
to bone, life expectancy <6months, current or prior osteonecrosis or osteomyelitis of the 
jaw, planned invasive dental procedure during study, malignant disease other than 
prostate cancer within the past 3 years, or creatinine clearance < 0.5 mL/s (the study 
excluded these individuals because zoledronic acid, the bisphosphonate being used, is 
contraindicated in these patients).1 
 
 Two central imaging readers assessed for SREs, radiologists were masked, and a 
third masked reviewer adjudicated discrepancies. These surveys were done at baseline 
12 
 
and every 12 weeks. The results of the study indicate that denosumab is better than 
zoledronic acid for delaying time to onset of SREs in study participants. The hazard ratio 
(HR) for time to first on-study SRE was 0.82 (95% CI, 0.71 to 0.95), an 18% reduction in 
time to first on-study SRE with use of denosumab.  The median months to first on-study 
SRE for denosumab and zoledronic acid were 20.7 (95% CI, 18.8 to 24.9) and 17.1 (95% 
CI, 15.0 to 19.4), respectively.  The median number of months on study at primary 
analysis cut-off date was 12.2 for denosumab and 11.2 for zoledronic acid.  Analysis of 
the secondary endpoint, time to first on-study SRE and subsequent on-study SREs, 
indicated a rate ratio of 0.884 and a calculated number needed to treat of 16, 
demonstrating that for every 16 patients treated with denosumab rather than zoledronic 
acid, one less will have an SRE. Results of the analysis of overall survival and disease 
progression between the two groups indicate there is not a statistically significant 
difference between the two groups. Median months of survival for denosumab and 
zoledronic acid were 19.4 (95% CI, 18.1 to 21.7) and 19.8 (95% CI 18.1 to 20.9), 
respectively. Median months to disease progression for denosumab (95% CI, 8.1 to 9.3) 
and zoledronic acid (95% CI, 8.2 to 9.3) was 8.4 months in each group.1   
Adverse events were assessed at baseline and every 4 weeks. The occurrence 
phase reactions were greater in the zoledronic acid group. The occurrence of death was 
about equal between groups. ONJ was a rare event in both groups. The occurrence of 
hypocalcemia and CTCAE grade 3 or 4 was higher in the denosumab group. The 
occurrence of events “potentially associated with renal impairment” were about the same 
in each group, with 15% occurring in the denosumab group and 16% in the zoledronic 
acid group.1 To review results of outcome measures, see Table III. 
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 Patients were analyzed based on intention to treat. However, only 228/950 in the 
denosumab group and 208/951 in the zoledronic acid group were on study at the primary 
data analysis cut-off date. The major reasons for discontinuation were death, withdrawal 
of consent and disease progression, and less than 5% per group were lost to follow up.1  
 
 In a similar double blind, randomized control trial published in 2010 by Stopeck 
et al3 denosumab was compared to zoledronic acid for analysis of the same primary (time 
to first on-study SRE for noninferiority) and secondary (time to first and subsequent on-
study SRE for superiority) endpoints in 2,046 participants from 322 centers in Europe, 
North America, South America, Japan, Australia, India and South Africa. Study 
participants were randomized into two groups to receive either 120 mg SQ denosumab 
plus IV placebo every 4 weeks (n = 1,026) or 4mg IV infusion of zoledronic acid plus SQ 
placebo every 4 weeks (n = 1,020). The study also assessed overall survival and disease 
progression. Other safety end points included incidence of treatment-emergent adverse 
events, changes in lab values, and incidence of anti-denosumab antibodies – all were 
coded using the Medical Dictionary for Regulatory activities (MedDRA v 12.0 system). 
Oral exams (for ONJ) were performed biannually by a blinded adjudication committee of 
an external panel of experts.3 
 Participants included in the study were of age ≥ 18 years old with histological or 
cytologically confirmed breast adenocarcinoma, a solid tumor, current or prior evidence 
of at least one bone metastasis, adequate organ function (including albumin-adjusted 
serum calcium at or between 8 and 11.5 mg/dL), and Eastern Cooperative Oncology 
Group (ECOG) performance status of 0, 1, or 2. Exclusion criteria were outlined as 
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follows: creatinine clearance <30mL/min using Cockcroft-Gault formula (due to 
contraindication of zoledronic acid use in this population), prior IV or oral 
bisphosphonate treatment for bone metastases, nonhealed dental/oral surgery, and prior 
malignancy within 3 years before random assignment.3  
 Participants in each group had similar baseline characteristics, which include: age, 
ECOG status, prior SRE, having more than 2 metastatic bone lesions, prior chemotherapy 
and hormonal therapy, prior use of oral bisphosphonates, median time from primary 
cancer diagnosis to diagnosis of bone metastasis, median time from diagnosis of bone 
metastasis to randomization, hormone receptor status (HR/PR), HER2 status, and 
presence of visceral metastasis.3   
 Patients were assessed by x-ray every 12 weeks for evidence of fracture, or by 
other radiographic imaging at their standard care appointments, which were scheduled at 
baseline and every 4 weeks. At least two blinded independent radiologists and a central 
imaging center performed assessment for both fracture and spinal cord compression. 
Results of the study indicate that denosumab was noninferior to zoledronic acid, and time 
to first on-study SRE was delayed by 18% with denosumab compared to zoledronic acid 
(HR, 0.82; 95% CI, 0.71 to 0.95; p<0.001 noninferiority; p = 0.01 superiority.)  The 
reported median time to onset of on-study SRE was 26.4 months with zoledronic acid, 
and was not reached during study with denosumab. The median number of months on 
study was 17, and the entire duration of the study, from enrollment to primary analysis, 
was 34 months.  Time to first and subsequent SREs was delayed by 23% with denosumab 
(rate ratio, 0.77; 95% CI, 0.66 to 0.89; p = 0.001). Assessment of overall survival (HR 
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0.95; 95% CI, 0.81 to 1.11) and disease progression (HR 1.00; 95% CI, 0.89 to 1.11) 
indicates similarity between the two groups.3  
Additional outcome measures for safety and efficacy were measured regularly. 
The rate of renal failure, acute phase reactions and common terminology criteria for 
adverse events (CTCAE) ≥ 3 occurred more commonly in the zoledronic acid group. The 
rate of hypocalcemia occurred more commonly with denosumab, and ONJ was a rare 
event in each group.3 To review results of outcome measures, see Table III. 
 In the statistical analysis, patients were analyzed based on intent to treat.  45% of 
the zoledronic acid group and 46% of the denosumab group remained on study at primary 
analysis cut-off date. 17% of patients in each group died before the studies completion, 
and this was the most common reason for discontinuation, followed by 12% disease 
progression and 12% consent withdrawal; <1% of each group was lost to follow up.3  
 
 The final study included in this review was a double blind, double dummy, RCT 
by Henry et al2 published in 2011. There were 1,779 participants from 321 centers 
worldwide.  Participants were randomized into two groups to receive either 120 mg SQ 
denosumab plus IV placebo every 4 weeks (n = 86) or 4mg IV infusion of zoledronic acid 
plus SQ placebo every 4 weeks (n = 890). Zoledronic acid was dose adjusted for renal 
impairment as indicated. Randomization was performed by an independent individual, 
and participants were stratified by tumor type, which were non-small cell lung cancer 
(40%), multiple myeloma (10%) and “other” (50%).  Participants in each group had 
similar baseline characteristics, including gender, age, ECOG status, primary tumor type, 
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prior SRE, median months from initial diagnosis of bone metastasis to randomization, 
prior “anti-neoplastic treatment”, and presence of visceral metastases.2 
 The same primary and secondary endpoints as the prior two studies were 
assessed in this trial. Exploratory endpoints include bone turnover markers measured at 
baseline and week 13, overall survival, and overall disease progression.2  
 Inclusion criteria for participants is outlined as follows: age ≥ 18 years old with 
histologically or cytologically confirmed solid tumors (except breast or prostate) or 
myeloma and radiographic evidence of at least 1 bone metastasis or osteolytic lesion, 
creatinine clearance ≥30 mL/min, and ECOG performance status ≤ 2.  Patients were 
excluded if they had prior treatment with IV bisphosphonates, planned radiation or 
surgery to bone, or unhealed dental/oral surgery.2   
 Blinded, external radiologists at a central imaging center performed assessment of 
outcomes at baseline, and every 12 weeks or at routine appointments as indicated. Results 
of the study indicate that denosumab is noninferior to zoledronic acid in delaying time to 
first on-study SRE (HR, 0.84; 95% CI, 0.71-0.98). This represents a 16% reduction in 
SREs with use of denosumab rather than zoledronic acid.  The total length of the study 
was 34 months, however, the reported median time to first on-study SRE was 20.6 
months in the denosumab group, and 16.3 months in the zoledronic acid group.  “Median 
time (quartile [Q]1, Q3) on study was approximately 7 months (Q1, 3; Q3, 14).” 2 
Assessment for time to first and subsequent SREs and superiority was not statistically 
significant (rate ratio 0.90, 95% CI, 0.77 to 1.04). These results indicate that there is 10% 
reduction in time to first and multiple SREs, with a NNT of 21. Overall survival (HR 
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0.95, 95% CI, 0.83 to 1.08) and disease progression (HR 1.00; 95% CI, 089-1.12) were 
similar between groups.2 
Adverse events were assessed at regular intervals by an external data monitoring 
committee. The incidence of renal failure, acute phase reactions, and CTCAE grade ≥ 3 
was greater in the zoledronic acid group.  The incidence of hypocalcemia was greater in 
the denosumab group, and the incidence of ONJ was rare in both groups.2  To review 
results of outcome measures, see Table III. 
In the statistical analysis, patients were analyzed based on intent to treat. Only 
20% of participants remained on-study at primary analysis cut-off date (zoledronic acid 
group, n=178; denosumab group, n=180).  The top 3 reasons for discontinuation were 
death (35%), disease progression (13%) and consent withdrawn (15%). Loss to follow up 
in the denosumab and zoledronic acid group was 2.5% and 1.8% respectively.2 
DISCUSSION 
Summary of main findings (Table II):  
  This review of studies 1-3 illustrates the increased benefit of denosumab compared 
to the standard treatment, bisphosphonates, in preventing or delaying time to onset of 
SREs in patients with solid tumor cancer and multiple myeloma. While these results are 
positive, it should be noted that the assessment of overall survival and disease 
progression was similar between groups in each of the trials reviewed.  Since overall 
survival and disease progression are similar with both agents, the decision regarding 
which therapy to use should also include review of adverse events associated with each 
agent individually, as well as ease of administration. 
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 An overview of selected adverse events can be found in Table III.  The adverse 
events that showed the greatest discrepancy between treatment arms were the incidence 
of renal failure, hypocalcemia and acute phase reactions. The rate of renal failure was 
higher in those receiving zoledronic acid. Because denosumab is not contraindicated in 
patients with renal impairment it is a potential option for those patients. The rate of ONJ 
was about the same between groups, but was a rare event. Additionally, the occurrence of 
acute phase reactions, including flu-like syndrome, were much higher in those taking 
zoledronic acid.  Hypocalcemia was more common in the denosumab group, but is easily 
managed by careful monitoring and supplementation as indicated.  With regard to ease of 
administration, denosumab is easier to administer with a subcutaneous injection rather 
than an IV infusion, which is required for zoledronic acid administration. 
Overall completeness and applicability of evidence 
A possible limitation consistent across studies is the difference between the 
number of participants at onset of each trial and at studies completion. Although, loss to 
follow up was minimal, the rate of death was quite high and cause of death, whether due 
to therapy or disease progression, was not clearly stratified in each of the studies.  One 
counter measure to this limitation is that each study was analyzed by the intention to treat 
principle, and each study maintained a sufficient number of participants to account for the 
significance of the results in spite of the high rate of deaths in each study. 
One notable limitation of the study authored by Henry et al 2 is that participants 
are not completely stratified by tumor type, but rather are characterized by the diagnosis 
of non-small cell lung cancer (40% of patients in each randomized group), multiple 
myeloma (10% of patients per randomized group), or “other” (50% of patients per 
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randomized group). The “other” category consists of participants with solid tumors, but 
because their tumor type is unknown, and they comprise at least half of the entire study 
population it may be difficult to confer particular relevance to these results in individual 
incidents.  
An additional limitation of these studies is that participants with creatinine 
clearance less than 30 mL/minute were excluded from each of the trials based on 
zoledronic acid protocol.  In studies comparing denosumab to placebo alone, these 
participants can be included because renal impairment is not a contraindication. 
However, in studies, such as those in this review, which are a head to head comparison of 
denosumab and zoledronic acid, participants with this level of renal impairment cannot 
be assessed. 
A further possible limitation of applicability, based on these studies, is the use of 
denosumab is patients who have used bisphosphonates in the past.  Prior bisphosphonate 
use by potential participants was part of the exclusion criteria in each of the trials. 
Another potential avenue of research includes use of denosumab in patients who have 
previously used bisphosphonates, with or without success, to determine if denosumab 
would in fact be more efficacious and potentially increase quality of life for these people.  
Quality of evidence 
 Each of the trials included in this review are randomized controlled trials that 
have been evaluated for quality using the GRADE criteria. Each study received a rating 
of “high”. The characteristics of reviewed studies can be found in Table I. 
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Potential biases in the review process 
 The funding source for each trial may have opened the window to potential for 
causing bias. Amgen funded and performed data collection and analysis of the Fizazi et al 
trial.1 Authors of the study, some of whom were employed by Amgen, interpreted the 
data. A medical writer provided by Amgen assisted the authors in drafting and reviewing 
the study. The study authored by Stopeck et al was “supported” by Amgen and Daiichi 
Sankyo. Some of the authors of the study did claim a financial interest in the subject and 
these individuals were clearly listed at the conclusion of the article. The authors of the 
study contributed to conception and design, provision of study material or patients, 
collection and assembly of data, data analysis and interpretation, manuscript writing, and 
final approval of manuscript.3 Research for the study authored by Henry et al was funded 
by several individuals (one of which is an author) from both Amgen and Novartis.2 The 
risk of bias was potentially reduced by the extensive degree of blinding in various aspects 
of each trial, including randomization, assessment of outcomes, and the double dummy 
design. 
CONCLUSION 
 The systematic review process has demonstrated that, based on findings in each of 
these high quality studies, denosumab is a better agent for delaying onset to SREs in 
patients with both solid tumors and multiple myeloma. Denosumab also has other 
advantages to be considered in practice. Denosumab does not require dose adjustment for 
renal impairment, nor is renal monitoring necessary during therapy. Also, it is less likely 
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to cause acute phase reactions, which may potentially reduce some burden of therapy for 
the patient.  Denosumab did, however, demonstrate a higher rate of hypocalcemia, which 
implies that therapy requires close monitoring and supplementation as indicated.   The 
benefits of improved effectiveness of therapy, ease of administration, and decrease in rate 
of adverse events may potentially be extended to another patient important outcome of an 
increase in quality of life.   
Research of supportive therapy for prevention of SREs in solid tumor and 
multiple myeloma patients has shown progress with the novel RANKL therapy. 
However, other physiological pathways, or improvements in the pharmacotherapeutics of 
current therapy should be addressed and considered in future research for the purposes of 
discovering both more effective, and less toxic therapy. 
In addition, further research of an increased duration is necessary to assess both 
the long-term effectiveness and risk of denosumab. Obviously, such research has not 
been possible due to the youth of denosumab. However, it should commence as soon as 
possible and be continued for a significant amount of time.  
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Table I. Characteristics of Reviewed Studies  
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Fizazi, K., et al 1 
 950 951 ≥18 yrs Yes Yes Yes Yes Yes D,12.2 
Z, 11.2 
Stopeck, A. et al.  2 
 1,026 1,020 ≥18 yrs Yes Yes Yes Yes Yes 17 
Henry, D., et al. 3 
 886 890 ≥18 yrs Yes Yes Yes Yes Yes 7 
D: Denosumab; ZA: Zoledronic Acid 
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Table II. Summary of Findings  
 
 
Median time to first 
on-study SRE  
(months) 
Hazard 
Ratio 
Time to subsequent 
on-study SREs 
Survival 
 
Disease 
progression 
 
Quality 
Importance of 
Outcome Critical  Critical Critical Critical  
Fizazi, K., et al 1 
D: 20.7 
ZA: 17.1 
0.82 RR = 0.884 
D: 19.4 
months 
ZA: 19.8 
months 
Median mo. 
D: 8.4  
ZA: 8.4  
HIGH 
Stopeck, A. et 
al.  3 
D: not reached 
ZA: 26.4 
0.82 
 
RR = 0.77 HR 0.95 HR 1.00 HIGH 
Henry, D., et al. 
2 
D: 20.6 
ZA: 16.3 
0.84 
 
RR = 0.90 HR 0.95 HR 1.00 HIGH 
D: Denosumab; ZA: Zoledronic Acid; RR: Rate Ratio; HR: Hazard Ratio 
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Table III. Summary of reported Adverse Events (Abbreviated)  
 
Den: Denosumab; ZA: Zoledronic Acid; ONJ: osteonecrosis of the jaw; CTCAE: 
Common Terminology Criteria for Adverse Events; NR: Not reported 
 
 
 
 ONJ Renal failure Hypocalcemia 
Acute phase 
reactions  
(first 3 days) 
CTCAE grade ≥ 3 (grade 5 listed 
separately in Fizazi) 
 Den ZA Den ZA Den ZA Den ZA Den ZA 
Fizazi, K. 1 2.0% 1.0% NR NR 13.0% 6.0% 8% 18% 
72% 
Grade 5 (death): 30% 
66% 
Grade 5: 29% 
Stopeck, A. 3 2.0% 1.4% 0.2% 2.5% 5.5% 3.4% 10.4% 27.3% 59.7% 62.7% 
Henry, D., et 
al 2 1.1% 1.3% 2.3% 2.8% 10.8% 5.8% 6.9% 14.5% 77% 80% 
